Dr. Michael Wyand, DVM, PhD is a biopharmaceutical executive with over twenty-five years experience in managing and building successful product and service oriented life science companies. He is the CEO and Director of Oxeia Biopharmaceuticals, a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction.
Dr. Vishal Bansal, M.D. F.A.C.S. is the Chief Scientific Officer and Co-Founder of Oxeia Biopharmaceuticals. Since 2015, Dr. Bansal is a Director of Trauma Surgery at Scripps Mercy Hospital in San Diego.
Oxeia Biopharmaceuticals is a privately held clinical stage biotech company developing drug treatments for concussion and underlying neuro-metabolic dysfunction. Oxeia has completed phase 2a testing on OXE103, a synthetic human ghrelin, an endogenous hormone. OXE103 freely crosses the blood-brain barrier addressing underlying neuro-metabolic dysfunction and axonal injury. OXE103 uniquely targets the hippocampus region of the brain, an area important for cognition and memory.
Oxeia’s phase 2a study showed robust treatment effect across study endpoints with 85% of OXE103 patients improving while only 33% improved with standard care alone. This was the first time any drug showed meaningful improvement in persistent concussion symptoms. Meaningful improvements were made in the reduction of symptom severity and the quality of life. See: oxeiabiopharma.com and startengine.com/offering/oxeia-biopharma for investment opportunity.